Evox Therapeutics Secures Major US Patent for Exosome Purification, Expanding Patent Portfolio

Evox Therapeutics Ltd, a pioneering exosome therapeutics company, is proud to announce that the US Patent and Trademark Office has granted the Company another patent for their innovative manufacturing process. This is the latest addition to the company’s expanding Intellectual Property portfolio and further cements Evox’s position as a leader in their field.

Evox has just been granted US Patent US11,640,272 for a revolutionary method of purifying engineered exosomes. This patent covers a process which is being widely used in the field of exosome therapeutics, and is a major breakthrough for Evox.

With four more manufacturing patents issued to Evox this year, the company now has protection for key purification and loading methods in key jurisdictions – a major step forward for the field of exosome therapeutics.

About Evox Therapeutics

Evox Therapeutics is revolutionizing the way rare diseases are treated. Based in Oxford, this privately-held biotechnology company has developed DeliverEX®, a proprietary technology that uses extracellular vesicles (EVs), known as exosomes, to deliver drugs to organs such as the brain and central nervous system.

By engineering exosomes for safe, non-immunogenic drug delivery, Evox is taking the limitations of gene therapy, gene editing, and RNA therapeutics head-on. Redmile and Orbimed are just two of the leading life sciences venture capital groups that have backed Evox and its comprehensive intellectual property portfolio.

Leave a Comment